Phase i clinical trial to determine maximum tolerated dose of oral albendazole in patients with advanced cancer

Cancer Chemotherapy and Pharmacology

Volumn 65, Issue 3, 2010, Pages 597-605

  Pourgholami, Mohammad H ^b   Szwajcer, Michael ^a   Chin, Melvin ^a,b   Liauw, Winston ^a,b   Seef, Jonathan ^c   Galettis, Peter ^a,b   Morris, David L ^b   Links, Matthew ^a,b  

^a ST GEORGE HOSPITAL   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c Southern Radiology   (Australia)

Author keywords

Albendazole; CA 125; Ovarian cancer; Phase I; Vascular endothelial growth factor

Indexed keywords

ALBENDAZOLE; VASCULOTROPIN; ANTINEOPLASTIC AGENT;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ARTICLE; BONE MARROW SUPPRESSION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG ERUPTION; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; FLUSHING; GASTROINTESTINAL SYMPTOM; HEMOPTYSIS; HUMAN; HYPERGLYCEMIA; HYPOALBUMINEMIA; HYPOKALEMIA; HYPONATREMIA; LEUKOPENIA; LYMPHOCYTOPENIA; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NEUROPATHY; NEUTROPENIA; PERIPHERAL EDEMA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; SOLID TUMOR; THROMBOCYTOPENIA; TREATMENT RESPONSE; VISUAL DISORDER; AREA UNDER THE CURVE; CHEMICALLY INDUCED DISORDER; DIARRHEA; DOSE RESPONSE; DRUG ADMINISTRATION; METABOLIC CLEARANCE RATE; METABOLISM; MIDDLE AGED; NAUSEA; NEOPLASM; ORAL DRUG ADMINISTRATION; PAIN; PATHOLOGY; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ALBENDAZOLE; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; DIARRHEA; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FATIGUE; FEMALE; HUMANS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; NAUSEA; NEOPLASMS; PAIN; TREATMENT OUTCOME;

EID: 75549089770     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-009-1157-8     Document Type: Article

References (24)

1. AD Dayan 2003 Albendazole, mebendazole and praziquantel. Review of non-clinical toxicity and pharmacokinetics Acta Trop 86 141 159 10.1016/S0001-706X(03)00031-7 1:CAS:528:DC%2BD3sXjs1CksLc%3D 12745134 (Pubitemid 36561365)
2. SE Marriner DL Morris B Dickson, et al. 1986 Pharmacokinetics of albendazole in man Eur J Clin Pharmacol 30 705 708 10.1007/BF00608219 1:CAS:528:DyaL28XmtFyhsb8%3D 3770064
3. J Sotelo H Jung 1998 Pharmacokinetic optimisation of the treatment of neurocysticercosis Clin Pharmacokinet 34 503 515 10.2165/00003088-199834060- 00006 1:CAS:528:DyaK1cXkt1eisrY%3D 9646011 (Pubitemid 28271899)
4. J Horton 2002 Albendazole: a broad spectrum anthelminthic for treatment of individuals and populations Curr Opin Infect Dis 15 599 608 1:CAS:528:DC%2BD38XptVShs70%3D 12821837
5. E Lacey RL Brady RK Prichard, et al. 1987 Comparison of inhibition of polymerisation of mammalian tubulin and helminth ovicidal activity by benzimidazole carbamates Vet Parasitol 23 105 119 10.1016/0304-4017(87)90029-X 1:CAS:528:DyaL2sXhs1ymsbo%3D 3564338
6. MH Pourgholami L Woon R Almajd, et al. 2001 In vitro and in vivo suppression of growth of hepatocellular carcinoma cells by albendazole Cancer Lett 165 43 49 10.1016/S0304-3835(01)00382-2 1:CAS:528:DC%2BD3MXhvVahtbw%3D 11248417 (Pubitemid 32206656)
7. J Sasaki R Ramesh S Chada, et al. 2002 The anthelmintic drug mebendazole induces mitotic arrest and apoptosis by depolymerizing tubulin in non-small cell lung cancer cells Mol Cancer Ther 1 1201 1209 1:CAS:528:DC%2BD3sXmvFOgsA%3D%3D 12479701
8. A Khalilzadeh KT Wangoo DL Morris, et al. 2007 Epothilone-paclitaxel resistant leukemic cells CEM/dEpoB300 are sensitive to albendazole: involvement of apoptotic pathways Biochem Pharmacol 74 407 414 10.1016/j.bcp.2007.05.006 1:CAS:528:DC%2BD2sXntFamurw%3D 17560963 (Pubitemid 46963241)
9. N Doudican A Rodriguez I Osman, et al. 2008 Mebendazole induces apoptosis via Bcl-2 inactivation in chemoresistant melanoma cells Mol Cancer Res 6 1308 1315 10.1158/1541-7786.MCR-07-2159 1:CAS:528:DC%2BD1cXpvVaru7w%3D 18667591
10. M Yenjerla C Cox L Wilson, et al. 2009 Carbendazim inhibits cancer cell proliferation by suppressing microtubule dynamics J Pharmacol Exp Ther 328 390 398 10.1124/jpet.108.143537 1:CAS:528:DC%2BD1MXhs1Khur0%3D 19001156
11. T Mukhopadhyay J Sasaki R Ramesh, et al. 2002 Mebendazole elicits a potent antitumor effect on human cancer cell lines both in vitro and in vivo Clin Cancer Res 8 2963 2969 1:CAS:528:DC%2BD38XnvVWitrY%3D 12231542
12. MH Pourgholami J Akhter L Wang, et al. 2005 Antitumor activity of albendazole against the human colorectal cancer cell line HT-29: in vitro and in a xenograft model of peritoneal carcinomatosis Cancer Chemother Pharmacol 55 425 432 10.1007/s00280-004-0927-6 1:CAS:528:DC%2BD2MXjtVWmtrw%3D 15565325 (Pubitemid 40568971)
13. D Martarelli P Pompei C Baldi, et al. 2008 Mebendazole inhibits growth of human adrenocortical carcinoma cell lines implanted in nude mice Cancer Chemother Pharmacol 61 809 817 10.1007/s00280-007-0538-0 1:CAS:528: DC%2BD1cXitleru7c%3D 17581752 (Pubitemid 351302037)
14. MH Pourgholami Z Yan Cai Y Lu, et al. 2006 Albendazole: a potent inhibitor of vascular endothelial growth factor and malignant ascites formation in OVCAR-3 tumor-bearing nude mice Clin Cancer Res 12 1928 1935 10.1158/1078-0432.CCR-05-1181 16551879
15. MH Pourgholami ZY Cai L Wang, et al. 2009 Inhibition of cell proliferation, vascular endothelial growth factor and tumor growth by albendazole Cancer Invest 27 171 177 10.1080/07357900802210752 1:CAS:528:DC%2BD1MXktFKitb4%3D 19235589
16. DL Morris JL Jourdan MH Pourgholami 2001 Pilot study of albendazole in patients with advanced malignancy. Effect on serum tumor markers/high incidence of neutropenia Oncology 61 42 46 10.1159/000055351 1:CAS:528: DC%2BD3MXmtF2qsrw%3D 11474247 (Pubitemid 32727586)
17. ZY Cai P Galettis Y Lu, et al. 2007 Pharmacokinetics of albendazole in New Zealand white rabbits: oral versus intraperitoneal administration Anticancer Res 27 417 422 1:CAS:528:DC%2BD2sXjs1Wntrk%3D 17352262
18. LI Alvarez SF Sanchez CE Lanusse 1999 In vivo and ex vivo uptake of albendazole and its sulphoxide metabolite by cestode parasites: relationship with their kinetic behaviour in sheep J Vet Pharmacol Ther 22 77 86 10.1046/j.1365-2885.1999.00194.x 1:CAS:528:DyaK1MXjvFOmt7Y%3D 10372592 (Pubitemid 29245864)
19. G Edwards AM Breckenridge 1988 Clinical pharmacokinetics of anthelmintic drugs Clin Pharmacokinet 15 67 93 1:CAS:528:DyaL1cXls1aktr8%3D 3064952
20. E Lacey TR Watson 1985 Structure-activity relationships of benzimidazole carbamates as inhibitors of mammalian tubulin, in vitro Biochem Pharmacol 34 1073 1077 10.1016/0006-2952(85)90611-2 1:CAS:528:DyaL2MXktVSiu7o%3D 3985991 (Pubitemid 15054415)
21. E Lacey TR Watson 1985 Activity of benzimidazole carbamates against L1210 mouse leukaemia cells: correlation with in vitro tubulin polymerization assay Biochem Pharmacol 34 3603 3605 10.1016/0006-2952(85)90742-7 1:CAS:528: DyaL28XivVektw%3D%3D 4052102 (Pubitemid 16252545)
22. GW Lubega RK Prichard 1991 Interaction of benzimidazole anthelmintics with Haemonchus contortus tubulin: binding affinity and anthelmintic efficacy Exp Parasitol 73 203 213 10.1016/0014-4894(91)90023-P 1:CAS:528:DyaK38XitlE%3D 1889474
23. MA Jordan K Kamath 2007 How do microtubule-targeted drugs work? An overview Curr Cancer Drug Targets 7 730 742 10.2174/156800907783220417 1:CAS:528:DC%2BD1cXhsFOnsbg%3D 18220533
24. HC Rawden GO Kokwaro SA Ward, et al. 2000 Relative contribution of cytochromes P-450 and flavin-containing monoxygenases to the metabolism of albendazole by human liver microsomes Br J Clin Pharmacol 49 313 322 10.1046/j.1365-2125.2000.00170.x 1:CAS:528:DC%2BD3cXjtl2hsb8%3D 10759686 (Pubitemid 30195273)